Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (151-160 of 293) with videos related to

Pageof 30
Sort By:
Oncogene|July 31, 2021
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN lossShuning He, Mark W Zimmerman, Hillary M Layden, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
The Journal of Clinical Investigation|November 2, 2012
Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirusScott J Rodig, Jingwei Cheng, Jacek Wardzala, et al.
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Cancer Cell|March 24, 2012
Activated ALK collaborates with MYCN in neuroblastoma pathogenesisShizhen Zhu, Jeong-Soo Lee, Feng Guo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivoJun Yang, Leonardo V Riella, Susanne Chock, et al.
Diabetes|September 1, 2010
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD miceAndrea Vergani, Francesca D'Addio, Mollie Jurewicz, et al.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.
Immunity|February 24, 2017
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaSuzanne George, Diana Miao, George D Demetri, et al.
Pageof 30

Showing results (151-160 of 293) with videos related to

Sort By:
Pageof 30
Oncogene|July 31, 2021
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN lossShuning He, Mark W Zimmerman, Hillary M Layden, et al.
Journal for Immunotherapy of Cancer|November 13, 2021
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trialPatrick A Ott, Matthew Nazzaro, Kathleen L Pfaff, et al.
The Journal of Clinical Investigation|November 2, 2012
Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirusScott J Rodig, Jingwei Cheng, Jacek Wardzala, et al.
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Cancer Cell|March 24, 2012
Activated ALK collaborates with MYCN in neuroblastoma pathogenesisShizhen Zhu, Jeong-Soo Lee, Feng Guo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2011
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivoJun Yang, Leonardo V Riella, Susanne Chock, et al.
Diabetes|September 1, 2010
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD miceAndrea Vergani, Francesca D'Addio, Mollie Jurewicz, et al.
Cell Reports. Medicine|October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironmentJames R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Cancer|April 26, 2017
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 studyEytan Ben-Ami, Constance M Barysauskas, Sarah Solomon, et al.
Immunity|February 24, 2017
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine LeiomyosarcomaSuzanne George, Diana Miao, George D Demetri, et al.
Pageof 30